CTLA4 and melanoma: Phase III trials have confirmed these findings showing improved outcomes for advanced-stage melanoma patients when treated with both anti-CTLA-4 and anti-PD-1 therapeutics, which showed benefits for patients with PD-L1 negative tumors (53).